SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.580-3.0%Oct 28 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dorightbythem who wrote (1199)10/22/2025 2:49:19 PM
From: bobbseytwins20014 Recommendations

Recommended By
CCS648
JJINV
Olecranon
waitwatchwander

  Read Replies (2) of 1216
 
Have to dispute the "no trials or data". We see trials everywhere to a fault. It's hard to picture PSS intentionally blowing up his net worth by seeing IBRX fail. We are worried about our shares, but PSS has shown that he cares about his as well. In the background lurks Anktiva, a compound that is certainly worth more than $2.40 per share. But, with all the negativity here going into third quarter sales and several possibilities
including more Anktiva approvals in the future this might be the time to be contrary.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News